Form 4: Teva Director Sells 50,000 Shares Under 10b5-1 Plan

Roberto Mignone, a director at Teva Pharmaceutical Industries, sold 50,000 ordinary shares for approximately $26.03 per share under a pre-arranged trading plan.

Summary

• Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd. (TEVA), sold 50,000 ordinary shares.
• The transaction occurred on November 26, 2025.
• The shares were sold at a weighted average price of $26.0301 per share, with prices ranging from $26.03 to $26.035.
• The sale was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following the transaction, Mr. Mignone directly holds 105,315 ordinary shares.
• He also indirectly holds 445,000 ordinary shares through Swiftcurrent Master Fund Ltd., where he is the manager of the investment adviser, though he disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of 50,000 shares by a director, even under a 10b5-1 plan, generally carries a slightly negative sentiment as it can be interpreted as an insider taking profits or reducing exposure. However, the 10b5-1 plan mitigates the immediate negative impact by indicating a pre-scheduled, non-event-driven transaction.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to immediate company news.

Negatives

• A director selling a significant number of shares (50,000) can be perceived as a negative signal by investors, potentially indicating a belief that the stock price may not rise significantly in the near term or a desire to diversify holdings.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This insider transaction is specific to Teva Pharmaceutical Industries Ltd. and does not directly reflect broader industry trends. However, investor sentiment towards the pharmaceutical sector can influence how such insider sales are perceived.

Related Party Transactions

• Roberto Mignone indirectly holds 445,000 ordinary shares through Swiftcurrent Master Fund Ltd., where he is the manager of the investment adviser, Bridger Management, LLC. He disclaims beneficial ownership except to the extent of his indirect pecuniary interest.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a negative signal, potentially leading to downward pressure on the stock price due to concerns about future performance or valuation.

Key Dates

Recommendation

While the sale by a director is generally a negative signal, the transaction was conducted under a pre-arranged 10b5-1 plan, which suggests it was not based on new, material non-public information. This mitigates the immediate negative implications. Investors should monitor future insider activity and company performance, but this single transaction does not warrant an immediate 'sell' recommendation unless combined with other negative indicators. A 'hold' position is prudent to assess broader company fundamentals.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Director Sale, Roberto Mignone, Stock Sale, 10b5-1 Plan, Ordinary Shares, Pharmaceuticals